propranolol has been researched along with Liver Neoplasms in 76 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol has changed the management of infantile hemangiomas (IHs)." | 9.01 | Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. ( López-Gutiérrez, JC, 2019) |
| "Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment." | 8.12 | Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022) |
| "To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)." | 8.12 | Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022) |
| "Transcatheter arterial embolization combined with propranolol is an effective treatment for life-threatening infantile hepatic hemangioendothelioma." | 7.96 | Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report. ( Guo, L; Li, J; Song, D; Wang, L; Wu, C; Yin, J, 2020) |
| "Although causes of cirrhosis and initial stages were similar in both groups using and not using propranolol, incidence of hepatocellular carcinoma was significantly lower in the propranolol group than in the group without propranolol." | 7.91 | Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center. ( Öcal, S; Özer Etik, D; Selçuk, H; Suna, N, 2019) |
| " In this study, we investigated the effect of propranolol, a non-selective beta-blocker on overall survival (OS) in unresectable/metastatic hepatocellular carcinoma (HCC) and on recurrence-free survival (RFS) in resectable, curable HCC." | 7.91 | The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. ( Chang, PY; Chang, WC; Chien, WC; Chung, CH; Dai, MS; Ho, CL; Lin, CS; Lin, HH, 2019) |
| "There have been reports of the use of levothyroxine or levothyroxine plus liothyronine for consumptive hypothyroidism caused by hepatic hemangiomas." | 7.85 | Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas. ( Hasegawa, Y; Higuchi, S; Takagi, M, 2017) |
| "Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications." | 7.85 | A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017) |
| "Clinical observation of conservative treatment of the left hemi-liver haemangioma by propranolol in the full-term newborn with initial symptoms of cardiac failure is presented." | 7.80 | [Clinical case of treatment of hepatic haemangioma by propranolol in the newborn]. ( Getman, AN; Ivleva, SA; Kucherov, IuI; Rekhviashvili, MG; Zhirkova, IuV, 2014) |
| "Propranolol bears antioxidant, anti-inflammatory, and antiangiogenic properties and antitumoral effects and therefore is potentially active in the prevention of hepatocellular carcinoma (HCC)." | 7.78 | Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. ( Aout, M; Beaugrand, M; Bourcier, V; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Roulot, D; Trinchet, JC; Vicaut, E, 2012) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 7.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol." | 7.77 | Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas." | 7.76 | Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010) |
| "Infantile hepatic hemangioma is the most common benign liver tumor during infancy." | 6.48 | Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012) |
| "Forty-five cases with IHH combined with complicated cutaneous IH were reviewed." | 5.91 | Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023) |
| "Hepatic hemangioma is the most common benign liver tumor." | 5.62 | [Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case]. ( Malla, I; Selzer Soria, EM, 2021) |
| " Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1." | 5.51 | Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report. ( Liu, HC; Tsai, MC; Yeung, CY, 2019) |
| "Diffuse hepatic hemangiomas are a challenging disease that can be life threatening." | 5.46 | Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol. ( Diaz, L; Levy, M; Warren, D, 2017) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "Propranolol has changed the management of infantile hemangiomas (IHs)." | 5.01 | Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. ( López-Gutiérrez, JC, 2019) |
| " The present report describes a case of multifocal IHH associated with subcutaneous and lingual hemangiomas, complicated by consumptive hypothyroidism and successfully managed with oral propranolol and thyroid replacement therapy, without documented adverse effects." | 4.31 | Multifocal Infantile Hepatic Hemangiomas Complicated by Consumptive Hypothyroidism: The Benefits of Early Diagnosis and Treatment. ( Alves, I; Coelho, J; Do Bom-Sucesso, M; Morais, CG; Vilares, AT, 2023) |
| "To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)." | 4.12 | Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022) |
| "Consumptive hypothyroidism due to cutaneous hemangioma and hepatic hemangioendothelioma can be managed with propranolol and low-dose sirolimus." | 4.12 | Severe consumptive hypothyroidism in hepatic hemangioendothelioma. ( Dubinski, I; Häberle, B; Küppers, J; Lurz, E; Schmid, I; Schmidt, H; Walther, A, 2022) |
| "Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment." | 4.12 | Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022) |
| "Transcatheter arterial embolization combined with propranolol is an effective treatment for life-threatening infantile hepatic hemangioendothelioma." | 3.96 | Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report. ( Guo, L; Li, J; Song, D; Wang, L; Wu, C; Yin, J, 2020) |
| "Although causes of cirrhosis and initial stages were similar in both groups using and not using propranolol, incidence of hepatocellular carcinoma was significantly lower in the propranolol group than in the group without propranolol." | 3.91 | Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center. ( Öcal, S; Özer Etik, D; Selçuk, H; Suna, N, 2019) |
| " In this study, we investigated the effect of propranolol, a non-selective beta-blocker on overall survival (OS) in unresectable/metastatic hepatocellular carcinoma (HCC) and on recurrence-free survival (RFS) in resectable, curable HCC." | 3.91 | The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. ( Chang, PY; Chang, WC; Chien, WC; Chung, CH; Dai, MS; Ho, CL; Lin, CS; Lin, HH, 2019) |
| "There have been reports of the use of levothyroxine or levothyroxine plus liothyronine for consumptive hypothyroidism caused by hepatic hemangiomas." | 3.85 | Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas. ( Hasegawa, Y; Higuchi, S; Takagi, M, 2017) |
| "Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications." | 3.85 | A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017) |
| "Clinical observation of conservative treatment of the left hemi-liver haemangioma by propranolol in the full-term newborn with initial symptoms of cardiac failure is presented." | 3.80 | [Clinical case of treatment of hepatic haemangioma by propranolol in the newborn]. ( Getman, AN; Ivleva, SA; Kucherov, IuI; Rekhviashvili, MG; Zhirkova, IuV, 2014) |
| " In this issue of the journal (beginning on page 1007), Nkontchou and colleagues report their retrospective observational finding that the β-blocker propranolol was associated with a highly statistically significant reduction in the incidence of hepatocellular carcinoma in patients with advanced cirrhosis and related esophageal varices." | 3.78 | Can propranalol prevent hepatocellular carcinoma? ( London, WT; McGlynn, KA, 2012) |
| "Propranolol bears antioxidant, anti-inflammatory, and antiangiogenic properties and antitumoral effects and therefore is potentially active in the prevention of hepatocellular carcinoma (HCC)." | 3.78 | Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. ( Aout, M; Beaugrand, M; Bourcier, V; Ganne-Carrie, N; Grando-Lemaire, V; Mahmoudi, A; Nkontchou, G; Roulot, D; Trinchet, JC; Vicaut, E, 2012) |
| "Nonselective β-blockers (NSBBs), such as propranolol, reportedly exert a pleiotropic effect in liver cirrhosis." | 3.78 | Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? ( Cho, YK; Chon, CU; Jeon, WK; Kim, BI; Kim, HJ; Kim, TW; Park, DI; Park, JH; Sohn, CI; Won, HS, 2012) |
| "We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol." | 3.77 | Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers." | 3.77 | β-blockers for infantile hemangiomas: a single-institution experience. ( Blatt, J; Buck, S; Burkhart, CN; Gold, S; Morrell, DS; Powell, C; Stavas, J; Zdanski, C, 2011) |
| "A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case." | 3.77 | Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011) |
| "We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas." | 3.76 | Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010) |
| "Infantile hepatic hemangioma is the most common benign liver tumor during infancy." | 2.48 | Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012) |
| "Forty-five cases with IHH combined with complicated cutaneous IH were reviewed." | 1.91 | Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023) |
| "Hepatic hemangioma is the most common benign liver tumor." | 1.62 | [Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case]. ( Malla, I; Selzer Soria, EM, 2021) |
| "Consumptive hypothyroidism is a rare paraneoplastic syndrome characterized by excessive inactivation of the thyroid hormones due to increased type 3 iodothyronine deiodinase activity of tumors." | 1.56 | A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas. ( Hong, KT; Kim, GB; Kim, YH; Ko, JS; Lee, YA; Lee, YJ; Shin, CH, 2020) |
| " Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1." | 1.51 | Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report. ( Liu, HC; Tsai, MC; Yeung, CY, 2019) |
| "Treatment with propranolol, with or without dexamethasone, may result in a favorable prognosis." | 1.48 | Huge fetal hepatic Hemangioma: prenatal diagnosis on ultrasound and prognosis. ( Bo-Yang, Y; Jiao-Ling, L; Kun-Shan, C; Qian, F; Qiu-Ming, H; Xiao-Fen, L; Xiu-Ping, G, 2018) |
| "Propranolol was added at different concentrations to HepG2 and HepG2." | 1.48 | Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells. ( Han, T; Liu, H; Lv, H; Tang, F; Wang, F; Wang, P; Xu, R; Zhang, X; Zhu, Z, 2018) |
| "Hepatic hemangioma is the third most common pediatric tumor, and it is rare in the neonatal period." | 1.48 | Neonatal giant hepatic hemangioma: A case report. ( Cai, P; Chen, J; Gu, Z; Huang, S; Wang, J; Wu, B; Zhu, J; Zhu, Z, 2018) |
| "Diffuse hepatic hemangiomas are a challenging disease that can be life threatening." | 1.46 | Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol. ( Diaz, L; Levy, M; Warren, D, 2017) |
| "The patient has hypoxemia due to abdominal distention during the follow-up period." | 1.46 | Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma. ( Bör, Ö; Düzenli Kar, Y; Kebapçı, M; Özdemir, ZC; Şöhret, NC, 2017) |
| "The new human hepatoma cell line HBG BC2 possesses the capacity of being reversibly differentiated in vitro and of maintaining a relatively higher metabolic rate when in the differentiated state (3 weeks) as compared to HepG2 cells, and thus may allow the conduct of repeated toxicity testing on cells in culture." | 1.32 | A new hepatoma cell line for toxicity testing at repeated doses. ( Arrivet, E; Bichet, N; Fabre, N; Prenez, A; Roome, NO; Trancard, J; Vericat, JA, 2003) |
| "Larger gastric varices have been shown to be the only risk factor for rebleeding (adjusted odds ratio, 4." | 1.31 | Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis. ( Chen, GH; Wu, CY; Yeh, HZ, 2002) |
| "Diltiazem was only stimulatory on 125I-LDL processing in leukocytes." | 1.30 | Effects of antihypertensive drugs on cholesterol metabolism of human mononuclear leukocytes and hepatoma cells. ( Behnke, B; Gebhardt, A; Naegele, H; Strohbeck, M, 1998) |
| "Metabolism of propranolol by the human hepatoma cell line Hep G2 was studied." | 1.28 | Induction of propranolol metabolism in the Hep G2 human hepatoma cell line. ( Steiner, A; Walle, T; Walle, UK, 1992) |
| "Verapamil induced an increase in the cellular cholesterol content in preloaded cells." | 1.28 | Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol. ( Auclair, M; Chappey-Gillet, B; Mazière, C; Mazière, JC; Salmon, S, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (11.84) | 18.7374 |
| 1990's | 4 (5.26) | 18.2507 |
| 2000's | 3 (3.95) | 29.6817 |
| 2010's | 45 (59.21) | 24.3611 |
| 2020's | 15 (19.74) | 2.80 |
| Authors | Studies |
|---|---|
| La Regina, G | 1 |
| Bai, R | 1 |
| Rensen, WM | 1 |
| Di Cesare, E | 1 |
| Coluccia, A | 1 |
| Piscitelli, F | 1 |
| Famiglini, V | 1 |
| Reggio, A | 1 |
| Nalli, M | 1 |
| Pelliccia, S | 1 |
| Da Pozzo, E | 1 |
| Costa, B | 1 |
| Granata, I | 1 |
| Porta, A | 1 |
| Maresca, B | 1 |
| Soriani, A | 1 |
| Iannitto, ML | 1 |
| Santoni, A | 1 |
| Li, J | 3 |
| Miranda Cona, M | 1 |
| Chen, F | 1 |
| Ni, Y | 1 |
| Brancale, A | 1 |
| Dondio, G | 1 |
| Vultaggio, S | 1 |
| Varasi, M | 1 |
| Mercurio, C | 1 |
| Martini, C | 1 |
| Hamel, E | 1 |
| Lavia, P | 1 |
| Novellino, E | 1 |
| Silvestri, R | 1 |
| Odaman Al, I | 1 |
| Demirağ, B | 1 |
| Erdem, M | 1 |
| Genç, S | 1 |
| Karapinar, TH | 1 |
| Ishikawa, T | 2 |
| Seki, K | 1 |
| Uchiyama, H | 1 |
| Wang, L | 2 |
| Song, D | 2 |
| Guo, L | 2 |
| Morais, CG | 1 |
| Alves, I | 1 |
| Coelho, J | 1 |
| Vilares, AT | 1 |
| Do Bom-Sucesso, M | 1 |
| Walther, A | 1 |
| Häberle, B | 1 |
| Küppers, J | 1 |
| Lurz, E | 1 |
| Schmid, I | 1 |
| Schmidt, H | 1 |
| Dubinski, I | 1 |
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Li, L | 2 |
| Yu, L | 1 |
| Xu, Z | 2 |
| Wei, L | 1 |
| Zhang, B | 1 |
| Han, X | 1 |
| Sun, Y | 1 |
| Ma, L | 1 |
| Lekwuttikarn, R | 1 |
| Josephs, S | 1 |
| Teng, JM | 1 |
| Joshi, K | 1 |
| Bolia, R | 1 |
| Poddar, U | 1 |
| Dabadgao, P | 1 |
| Kim, YH | 1 |
| Lee, YA | 1 |
| Shin, CH | 1 |
| Hong, KT | 1 |
| Kim, GB | 1 |
| Ko, JS | 1 |
| Lee, YJ | 1 |
| Wu, C | 1 |
| Yin, J | 1 |
| Macdonald, A | 1 |
| Durkin, N | 1 |
| Deganello, A | 1 |
| Sellars, ME | 1 |
| Makin, E | 1 |
| Davenport, M | 1 |
| Bucatariu, SM | 1 |
| Constantin, M | 1 |
| Varganici, CD | 1 |
| Rusu, D | 1 |
| Nicolescu, A | 1 |
| Prisacaru, I | 1 |
| Carnuta, M | 1 |
| Anghelache, M | 1 |
| Calin, M | 1 |
| Ascenzi, P | 1 |
| Fundueanu, G | 1 |
| Selzer Soria, EM | 1 |
| Malla, I | 1 |
| Cao, M | 1 |
| Huang, W | 1 |
| Chen, Y | 1 |
| Li, G | 1 |
| Liu, N | 1 |
| Wu, Y | 1 |
| Wang, G | 1 |
| Li, Q | 1 |
| Kong, D | 1 |
| Xue, T | 1 |
| Yang, N | 1 |
| Liu, Y | 1 |
| Maaloul, I | 1 |
| Aloulou, H | 1 |
| Hentati, Y | 1 |
| Kamoun, T | 1 |
| Mnif, Z | 1 |
| Hachicha, M | 1 |
| Kawahara, Y | 1 |
| Nijima, H | 1 |
| Suzuki, Y | 1 |
| Furukawa, R | 1 |
| Morimoto, A | 1 |
| Higuchi, S | 1 |
| Takagi, M | 1 |
| Hasegawa, Y | 1 |
| Özdemir, ZC | 1 |
| Düzenli Kar, Y | 1 |
| Şöhret, NC | 1 |
| Kebapçı, M | 1 |
| Bör, Ö | 1 |
| Warren, D | 1 |
| Diaz, L | 1 |
| Levy, M | 1 |
| Jiao-Ling, L | 1 |
| Xiu-Ping, G | 1 |
| Kun-Shan, C | 1 |
| Qiu-Ming, H | 1 |
| Xiao-Fen, L | 1 |
| Bo-Yang, Y | 1 |
| Qian, F | 1 |
| Wang, F | 2 |
| Liu, H | 1 |
| Xu, R | 1 |
| Wang, P | 1 |
| Tang, F | 1 |
| Zhang, X | 1 |
| Zhu, Z | 2 |
| Lv, H | 1 |
| Han, T | 1 |
| Cai, P | 1 |
| Zhu, J | 1 |
| Chen, J | 1 |
| Wu, B | 1 |
| Gu, Z | 1 |
| Huang, S | 1 |
| Wang, J | 1 |
| López-Gutiérrez, JC | 1 |
| Tsai, MC | 1 |
| Liu, HC | 1 |
| Yeung, CY | 1 |
| Yang, K | 1 |
| Feng, L | 1 |
| Chen, S | 2 |
| Ji, Y | 2 |
| Suna, N | 1 |
| Özer Etik, D | 1 |
| Öcal, S | 1 |
| Selçuk, H | 1 |
| Chang, PY | 1 |
| Chung, CH | 1 |
| Chang, WC | 1 |
| Lin, CS | 1 |
| Lin, HH | 1 |
| Dai, MS | 1 |
| Ho, CL | 1 |
| Chien, WC | 1 |
| Jiang, W | 1 |
| Li, Y | 1 |
| Li, ZZ | 1 |
| Sun, J | 1 |
| Li, JW | 1 |
| Wei, W | 1 |
| Zhang, C | 1 |
| Huang, C | 1 |
| Yang, SY | 1 |
| Yang, J | 1 |
| Kong, GY | 1 |
| Li, ZF | 1 |
| Emad, A | 1 |
| Fadel, S | 1 |
| El Wakeel, M | 1 |
| Nagy, N | 1 |
| Zamzam, M | 1 |
| Kieran, MW | 1 |
| El Haddad, A | 1 |
| Fernández Ibieta, M | 1 |
| Méndez Aguirre, NA | 1 |
| Girón Vallejo, O | 1 |
| Ruiz Jiménez, JI | 1 |
| Ferrandiz, L | 1 |
| Toledo-Pastrana, T | 1 |
| Moreno-Ramirez, D | 1 |
| Bardallo-Cruzado, L | 1 |
| Perez-Bertolez, S | 1 |
| Luna-Lagares, S | 1 |
| Rios-Martin, JJ | 1 |
| Cavalli, R | 1 |
| Novotna, V | 1 |
| Buffon, RB | 1 |
| Gelmetti, C | 1 |
| Kucherov, IuI | 1 |
| Zhirkova, IuV | 1 |
| Getman, AN | 1 |
| Ivleva, SA | 1 |
| Rekhviashvili, MG | 1 |
| Vergine, G | 3 |
| Sorci, M | 1 |
| Rosafio, C | 1 |
| Bigucci, B | 1 |
| Filippini, B | 1 |
| Ancora, G | 1 |
| Sorski, L | 1 |
| Melamed, R | 1 |
| Matzner, P | 1 |
| Lavon, H | 1 |
| Shaashua, L | 1 |
| Rosenne, E | 1 |
| Ben-Eliyahu, S | 1 |
| Xiang, B | 1 |
| Jiang, X | 1 |
| Liu, X | 1 |
| Wang, Q | 1 |
| Lu, G | 1 |
| Yang, L | 1 |
| Varrasso, G | 1 |
| Schiavetti, A | 1 |
| Lanciotti, S | 1 |
| Sapio, M | 1 |
| Ferrara, E | 1 |
| De Grazia, A | 1 |
| Clerico, A | 1 |
| Matsuura, T | 1 |
| Kadono, T | 1 |
| Koizumi, H | 1 |
| Kawakami, T | 1 |
| Soma, Y | 1 |
| Sarıalioğlu, F | 2 |
| Yazıcı, N | 1 |
| Erbay, A | 2 |
| Boyvat, F | 1 |
| Demir, Ş | 2 |
| Özçay, F | 1 |
| Uslu, N | 1 |
| Marsciani, A | 2 |
| Pericoli, R | 1 |
| Alaggio, R | 1 |
| Brisigotti, M | 1 |
| Mazereeuw-Hautier, J | 1 |
| Hoeger, PH | 1 |
| Benlahrech, S | 1 |
| Ammour, A | 1 |
| Broue, P | 1 |
| Vial, J | 1 |
| Ohanessian, G | 1 |
| Léauté-Labrèze, C | 1 |
| Labenne, M | 1 |
| Vabres, P | 1 |
| Rössler, J | 1 |
| Bodemer, C | 1 |
| Meyer, L | 1 |
| Graffstaedt, H | 1 |
| Giest, H | 1 |
| Truebenbach, J | 1 |
| Waner, M | 1 |
| Fusilli, G | 1 |
| Merico, G | 1 |
| Gurrado, R | 1 |
| Rosa, T | 1 |
| Acquafredda, A | 1 |
| Cavallo, L | 1 |
| Iavarone, M | 1 |
| Perrino, M | 1 |
| Viganò, M | 1 |
| Beck-Peccoz, P | 1 |
| Fugazzola, L | 1 |
| Thevenot, T | 1 |
| Cervoni, JP | 1 |
| Di Martino, V | 1 |
| Muthamilselvan, S | 1 |
| Vinoth, PN | 1 |
| Vilvanathan, V | 1 |
| Ninan, B | 1 |
| Amboiram, P | 1 |
| Sai, V | 1 |
| Anand, V | 1 |
| Scott, JX | 1 |
| Morais, P | 1 |
| Magina, S | 1 |
| Mateus, M | 1 |
| Trindade, E | 1 |
| Jesus, JM | 1 |
| Azevedo, F | 1 |
| Tan, ST | 1 |
| Itinteang, T | 1 |
| Leadbitter, P | 1 |
| Blatt, J | 1 |
| Morrell, DS | 1 |
| Buck, S | 1 |
| Zdanski, C | 1 |
| Gold, S | 1 |
| Stavas, J | 1 |
| Powell, C | 1 |
| Burkhart, CN | 1 |
| Zheng, JW | 1 |
| Bosemani, T | 1 |
| Puttgen, KB | 1 |
| Huisman, TA | 1 |
| Tekes, A | 1 |
| Avagyan, S | 1 |
| Klein, M | 1 |
| Kerkar, N | 1 |
| Demattia, A | 1 |
| Blei, F | 1 |
| Lee, S | 1 |
| Rosenberg, HK | 1 |
| Arnon, R | 1 |
| Nkontchou, G | 1 |
| Aout, M | 1 |
| Mahmoudi, A | 1 |
| Roulot, D | 1 |
| Bourcier, V | 1 |
| Grando-Lemaire, V | 1 |
| Ganne-Carrie, N | 1 |
| Trinchet, JC | 1 |
| Vicaut, E | 1 |
| Beaugrand, M | 1 |
| London, WT | 1 |
| McGlynn, KA | 1 |
| Kim, TW | 1 |
| Kim, HJ | 1 |
| Chon, CU | 1 |
| Won, HS | 1 |
| Park, JH | 1 |
| Park, DI | 1 |
| Cho, YK | 1 |
| Sohn, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Pedini, A | 1 |
| Brocchi, S | 1 |
| Marsciani, M | 1 |
| Desiderio, E | 1 |
| Bertelli, S | 1 |
| Vecchi, V | 1 |
| Baranowski, S | 1 |
| Winkler, A | 1 |
| Kunzi-Rapp, K | 1 |
| Schaal, M | 1 |
| Hempel, S | 1 |
| Debatin, KM | 1 |
| Posovszky, C | 1 |
| Wu, CY | 1 |
| Yeh, HZ | 1 |
| Chen, GH | 1 |
| Fabre, N | 1 |
| Arrivet, E | 1 |
| Trancard, J | 1 |
| Bichet, N | 1 |
| Roome, NO | 1 |
| Prenez, A | 1 |
| Vericat, JA | 1 |
| Poynard, T | 1 |
| Naveau, S | 1 |
| Poitrine, A | 1 |
| Lebourgeois, P | 1 |
| Hilpert, G | 1 |
| Chaput, JC | 1 |
| Ackerman, NB | 1 |
| Makohon, S | 1 |
| Naegele, H | 1 |
| Behnke, B | 1 |
| Gebhardt, A | 1 |
| Strohbeck, M | 1 |
| Narimatsu, S | 1 |
| Kobayashi, N | 1 |
| Asaoka, K | 1 |
| Masubuchi, Y | 1 |
| Horie, T | 1 |
| Hosokawa, M | 1 |
| Ohmori, S | 1 |
| Kitada, M | 1 |
| Miyano, J | 1 |
| Kataoka, H | 1 |
| Yamamoto, S | 1 |
| Gurkalo, VK | 1 |
| Zabezhinskiĭ, MA | 1 |
| Okamura, N | 1 |
| Terayama, H | 1 |
| Boyd, H | 2 |
| Martin, TJ | 2 |
| Shwed, JA | 1 |
| Walle, UK | 2 |
| Walle, T | 2 |
| Steiner, A | 1 |
| Chappey-Gillet, B | 1 |
| Salmon, S | 1 |
| Mazière, C | 1 |
| Auclair, M | 1 |
| Mazière, JC | 1 |
| Ohzato, H | 1 |
| Gotoh, M | 1 |
| Monden, M | 1 |
| Okamura, J | 1 |
| Mori, T | 1 |
| Dybing, E | 1 |
| Louis, CJ | 1 |
| Harrison, TS | 1 |
| Freier, DT | 1 |
| Cohen, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870] | Phase 4 | 36 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for propranolol and Liver Neoplasms
| Article | Year |
|---|---|
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid.
Topics: Adrenergic beta-Antagonists; Child; Female; Glucocorticoids; Health Care Costs; Hemangioma; Humans; | 2019 |
Multiple cutaneous and hepatic infantile hemangiomas having a successful response to propranolol as monotherapy at neonatal period.
Topics: Adrenergic beta-Antagonists; Disease Management; Female; Hemangioma; Humans; Infant, Newborn; Liver | 2013 |
"Cyrano nose" associated with hepatic hemangiomas successfully treated with propranolol.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Liver Neoplasms; | 2015 |
Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature.
Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Glucocorticoids; Heart Failure; Hema | 2012 |
1 trial available for propranolol and Liver Neoplasms
| Article | Year |
|---|---|
Clinical features and management of multifocal hepatic hemangiomas in children: a retrospective study.
Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P | 2016 |
70 other studies available for propranolol and Liver Neoplasms
| Article | Year |
|---|---|
Toward highly potent cancer agents by modulating the C-2 group of the arylthioindole class of tubulin polymerization inhibitors.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyto | 2013 |
A Retrospective Analysis of Clinical Characteristics, Treatment Modalities and Outcome of the Patients With Infantile Hepatic Hemangiomas: Single-center Experience From Turkey.
Topics: Adrenal Cortex Hormones; Hemangioma; Humans; Infant; Infant, Newborn; Liver Neoplasms; Propranolol; | 2023 |
Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Liver Neoplasms; Propranolol; Tr | 2022 |
Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma.
Topics: Child; Embolization, Therapeutic; Female; Heart Failure; Hemangioma; Hemangioma, Capillary; Humans; | 2022 |
Multifocal Infantile Hepatic Hemangiomas Complicated by Consumptive Hypothyroidism: The Benefits of Early Diagnosis and Treatment.
Topics: Child; Early Diagnosis; Hemangioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Propranolol | 2023 |
Severe consumptive hypothyroidism in hepatic hemangioendothelioma.
Topics: Hemangioendothelioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Male; Propranolol; Sirolimus; | 2022 |
Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment.
Topics: Child, Preschool; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Retrospective Studies; S | 2023 |
Successful Medical Management of Life-threatening Hepatic Hemangioma in Neonates.
Topics: Drug Therapy, Combination; Embolization, Therapeutic; Female; Glucocorticoids; Hemangioma; Hepatic A | 2019 |
Consumptive Hypothyroidism Due to Diffuse Hepatic Hemangiomas Treated With Propranolol Therapy.
Topics: Hemangioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Propranolol; Thyroid Hormones; Treatmen | 2020 |
A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Cholestasis; Drug Therapy, Combination; Heart | 2020 |
Infantile hepatic hemangioendothelioma associated with pulmonary artery hypertension and cardiac insufficiency successfully treated with transcatheter arterial embolization and propranolol: A case report.
Topics: Antihypertensive Agents; Catheterization; Combined Modality Therapy; Embolization, Therapeutic; Hear | 2020 |
Historical and Contemporary Management of Infantile Hepatic Hemangioma: A 30-year Single-center Experience.
Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Embolization, Therapeutic; Female; | 2022 |
A new sponge-type hydrogel based on hyaluronic acid and poly(methylvinylether-alt-maleic acid) as a 3D platform for tumor cell growth.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Diphenhydramine; Hep G2 Cells; Humans; Hy | 2020 |
[Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case].
Topics: Hemangioma; Humans; Infant, Newborn; Kasabach-Merritt Syndrome; Liver Neoplasms; Propranolol | 2021 |
Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through β-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
Topics: Adrenergic beta-Antagonists; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL5; | 2021 |
Infantile hepatic hemangioendothelioma successfully treated by low dose of propranolol.
Topics: Dose-Response Relationship, Drug; Female; Hemangioendothelioma; Humans; Infant; Liver Neoplasms; Pro | 2017 |
Successful use of propranolol for congenital hepatic hemangioma with Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Humans; Infant, Newborn; Kasabach-Merritt Syndrome; Liver Neoplasms; Ma | 2017 |
Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas.
Topics: Hemangioma; Hormone Replacement Therapy; Humans; Hypothyroidism; Infant; Liver; Liver Neoplasms; Mal | 2017 |
Beta blocker and steroid therapy in the treatment of infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-Antagonists; Glucocorticoids; Hemangioendothelioma; Hepatomegaly; Humans; Hypothyroi | 2017 |
Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Immunosuppressive Agents; Infant, Newborn; Liver; L | 2017 |
Huge fetal hepatic Hemangioma: prenatal diagnosis on ultrasound and prognosis.
Topics: Adult; Contrast Media; Dexamethasone; Female; Glucocorticoids; Hemangioma; Humans; Infant, Newborn; | 2018 |
Propranolol suppresses the proliferation and induces the apoptosis of liver cancer cells.
Topics: Adrenergic beta-Antagonists; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Cell Cycle; Cell Line | 2018 |
Neonatal giant hepatic hemangioma: A case report.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Newborn; Liver; Liver Neoplasms; Ma | 2018 |
Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol | 2019 |
Progressive infantile hepatic hemangioma not responding to propranolol.
Topics: Adrenergic beta-Antagonists; Age of Onset; Child, Preschool; Disease Progression; Fatal Outcome; Fem | 2019 |
Effect of Propranolol Treatment on the Incidence of Hepatocellular Carcinoma in Patients Waiting for Liver Transplant With Cirrhosis: A Retrospective, Surveillance Study in a Tertiary Center.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; | 2019 |
The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male | 2019 |
Chronic restraint stress promotes hepatocellular carcinoma growth by mobilizing splenic myeloid cells through activating β-adrenergic signaling.
Topics: Adrenergic Agents; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemoki | 2019 |
Outcome of Children Treated for Infantile Hepatic Hemangioendothelioma.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Female; Follow-Up Studies; Hemangioendot | 2020 |
[Rapid response of a multifocal liver hemangioma to propranolol treatment].
Topics: Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Remission Induction; Time Factors | 2013 |
Diffuse neonatal hemangiomatosis with partial response to propranolol.
Topics: Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Propranolol; Skin Neoplasms; Vasodilat | 2014 |
[Clinical case of treatment of hepatic haemangioma by propranolol in the newborn].
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemangioma; | 2014 |
Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through β-adrenoceptors blockade and COX2 inhibition.
Topics: Adrenergic beta-Agonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Cyclo | 2016 |
Propranolol as first-line treatment for life-threatening diffuse infantile hepatic hemangioma: A case report.
Topics: Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Remission Induction; Severity of I | 2017 |
Successful propranolol treatment for diffuse neonatal hemangiomatosis.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Magnetic Resonan | 2017 |
A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University.
Topics: Age of Onset; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Critical Pathways; Female; | 2017 |
Massive response of severe infantile hepatic hemangioma to propanolol.
Topics: Antineoplastic Agents, Phytogenic; Female; Hemangioma, Capillary; Humans; Infant; Liver Neoplasms; P | 2010 |
Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.
Topics: Adrenal Cortex Hormones; Female; Heart Failure; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P | 2010 |
Effectiveness of propranolol in a newborn with liver hemangiomatosis.
Topics: Cardiovascular Agents; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol | 2010 |
Propranolol for infantile haemangiomas and neuroglycopenic seizures.
Topics: Adrenergic beta-Antagonists; Blood Glucose; Hemangioma; Humans; Hyperphagia; Hypoglycemia; Infant; L | 2010 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, C | 2010 |
Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Hemangioendothelioma; Hum | 2010 |
[Beta-blockers in portal hypertension: Unexpected limitations!].
Topics: Adrenergic beta-Antagonists; Cause of Death; Esophageal and Gastric Varices; Esophagoscopy; Gastroin | 2011 |
Hepatic haemangioma of infancy: role of propranolol.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Low Birth Weight; Infant, Newborn; | 2010 |
Efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Infant; Liver Neoplas | 2011 |
Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Follow-Up Studies; Hemangioma; Humans | 2011 |
β-blockers for infantile hemangiomas: a single-institution experience.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Drug Monitoring; Female; | 2011 |
Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Liver Neoplasms; Neop | 2011 |
Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-2 Receptor Antagonists; Antineoplastic Agents; Congenital Hypothyroidism; Drug Monit | 2013 |
Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis.
Topics: Aged; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Human | 2012 |
Can propranalol prevent hepatocellular carcinoma?
Topics: Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; M | 2012 |
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Alcohol Drinking; Carcinoma, Hepatocellular; Female; Follo | 2012 |
Efficacy of propranolol treatment in thyroid dysfunction associated with severe infantile hepatic hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Sever | 2012 |
[Infantile hepatic hemangiomas: first-line propranolol monotherapy as new treatment strategy?].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Beckwith-Wiedemann Syndrome; Female; Follow-Up St | 2012 |
Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis.
Topics: Adrenergic beta-Antagonists; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gast | 2002 |
A new hepatoma cell line for toxicity testing at repeated doses.
Topics: Acetaminophen; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Dru | 2003 |
Recurrent bleeding and propranolol?
Topics: Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Live | 1983 |
The blood supply of experimental liver metastases. VII. Further studies on increased tumor vascularity caused by epinephrine.
Topics: Animals; Carcinoma 256, Walker; Epinephrine; Liver Neoplasms; Liver Neoplasms, Experimental; Microci | 1984 |
Effects of antihypertensive drugs on cholesterol metabolism of human mononuclear leukocytes and hepatoma cells.
Topics: Antihypertensive Agents; Carcinoma, Hepatocellular; Cholesterol; Diltiazem; Humans; Leukocytes, Mono | 1998 |
High-performance liquid chromatographic analysis of the sulfation of 4-hydroxypropranolol enantiomers by monkey liver cytosol.
Topics: Adult; Aged; Animals; Arylsulfotransferase; Carcinoma, Hepatocellular; Chromatography, High Pressure | 2001 |
[Modification of chemical carcinogenesis with adrenergic compounds].
Topics: Adrenergic alpha-Antagonists; Animals; Cell Transformation, Neoplastic; Diethylnitrosamine; Drug Ant | 1978 |
Comparison of the epinephrine-mediated activation of adenylate cyclase in plasma membranes from liver and ascites hepatomas of rats.
Topics: Adenylyl Cyclases; Animals; Carcinoma, Hepatocellular; Cell Membrane; Enzyme Activation; Epinephrine | 1976 |
The effect of propranolol on induction of rat liver tumors by a chemical carcinogen.
Topics: Animals; Diet; Drug Interactions; Liver Neoplasms; Male; Methyldimethylaminoazobenzene; Neoplasms, E | 1977 |
Hep G2 cell line as a human model for sulphate conjugation of drugs.
Topics: Arylsulfotransferase; Carcinoma, Hepatocellular; Dopamine; Humans; Liver; Liver Neoplasms; Nitrophen | 1992 |
Induction of propranolol metabolism in the Hep G2 human hepatoma cell line.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Monoamine Oxidase Inhibitors; Oxidation-Reductio | 1992 |
Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol.
Topics: Calcium Channel Blockers; Carcinoma, Hepatocellular; Cholesterol; Humans; Hydrolysis; Lipoproteins, | 1990 |
[Effect of propranolol on intractable ascites following liver resection].
Topics: Adrenergic beta-Antagonists; Ascitic Fluid; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Ci | 1986 |
Effects of membrane stabilizers on glucuronidation and amino acid transport in cultures of rat hepatoma cells.
Topics: Alanine; Aminoisobutyric Acids; Animals; Antipsychotic Agents; Biological Transport; Carcinoma, Hepa | 1973 |
Activity and hormone responsiveness of adenyl cyclase during induction of tumors in rat liver with 3'-methyl-4-dimethylaminoazobenzene.
Topics: Adenylyl Cyclases; Animals; Carcinoma, Hepatocellular; Cell Fractionation; Diet; Enzyme Activation; | 1974 |
Proceedings: Recurrent pheochromocytoma.
Topics: Abdominal Neoplasms; Adolescent; Adrenal Gland Neoplasms; Adult; Child; Epinephrine; Female; Hormone | 1974 |